- Home
- MOV vs XERS Comparison
MOV vs XERS Comparison
Compare MOV & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOV
- XERS
- Stock Information
- Founded
- MOV 1961
- XERS 2005
- Country
- MOV United States
- XERS United States
- Employees
- MOV N/A
- XERS N/A
- Industry
- MOV Consumer Specialties
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- MOV Consumer Discretionary
- XERS Health Care
- Exchange
- MOV Nasdaq
- XERS Nasdaq
- Market Cap
- MOV 441.7M
- XERS 500.2M
- IPO Year
- MOV 1993
- XERS 2018
- Fundamental
- Price
- MOV $19.49
- XERS $3.34
- Analyst Decision
- MOV Strong Buy
- XERS Buy
- Analyst Count
- MOV 2
- XERS 3
- Target Price
- MOV $36.25
- XERS $4.87
- AVG Volume (30 Days)
- MOV 123.4K
- XERS 1.3M
- Earning Date
- MOV 12-05-2024
- XERS 03-05-2025
- Dividend Yield
- MOV 7.18%
- XERS N/A
- EPS Growth
- MOV N/A
- XERS N/A
- EPS
- MOV 1.05
- XERS N/A
- Revenue
- MOV $658,329,000.00
- XERS $187,361,000.00
- Revenue This Year
- MOV N/A
- XERS $24.27
- Revenue Next Year
- MOV $4.31
- XERS $18.57
- P/E Ratio
- MOV $18.56
- XERS N/A
- Revenue Growth
- MOV N/A
- XERS 22.72
- 52 Week Low
- MOV $17.86
- XERS $1.69
- 52 Week High
- MOV $29.45
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- MOV 48.60
- XERS 49.66
- Support Level
- MOV $18.56
- XERS $3.14
- Resistance Level
- MOV $19.54
- XERS $3.60
- Average True Range (ATR)
- MOV 0.56
- XERS 0.17
- MACD
- MOV -0.03
- XERS -0.02
- Stochastic Oscillator
- MOV 52.84
- XERS 37.74
About MOV Movado Group Inc.
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.